HC Wainwright & Co. Maintains Buy on Perspective Therapeutics, Raises Price Target to $13

HC Wainwright & Co. analyst Robert Burns has maintained a Buy rating on Perspective Therapeutics (AMEX: CATX) and raised the price target from $12 to $13. This adjustment reflects a positive outlook on the company's performance.